Endometrioid adenocarcinoma stage 1c does not need olaparib. Endometrioid adenocarcinoma stage 1c belongs to early stage cancer, surgery combined with radiotherapy is able to achieve better therapeutic effect or even cure, and it is not recommended to add other therapeutic means. Olaparib belongs to targeted drugs, which is mainly applied to advanced ovarian cancer with BRCA gene mutation and advanced breast cancer, and is not routinely applied in endometrial cancer. Therefore, olaparib in endometrial cancer in the clinical lack of basis, advanced stage can be considered for clinical research. Stage 1c endometrioid adenocarcinoma itself has better treatment means and effect, there is no need to add other treatment means. It is recommended to choose the appropriate treatment under the guidance of the doctor and actively treat the disease to avoid delay.